Abstract
Protein kinases function in key steps in several physiopathological events; therefore the development of specific inhibitors to these enzymes presents new opportunities for the treatment of various diseases. Glycogen synthase kinase 3 (GSK-3) is a constitutively active serine/threonine kinase, whose dysfunction has been linked to several cases of insulin-resistant type 2 diabetes mellitus, Alzheimer’s disease and mood disorders. These findings make GSK-3 an attractive target for therapeutics, and several research groups and pharmaceutical companies have made significant efforts to develop new inhibitors with selective activity to different GSK-3 pathways. One of the strategies applied in the development of new inhibitors is based on protein-protein interactions between substrates or docking proteins of specific proteins kinases, creating peptides modulators designed to specifically inhibit those enzymes. Here, we discuss the development, signaling and the patent applications of specific peptides designed to inhibit GSK-3, their patent status and their potential uses in the treatment of GSK-3 specific pathologies.
Keywords: Diabetes mellitus, GSK-3, intracellular signaling, peptide modulator, protein-protein interaction, rational peptide design.
Current Signal Transduction Therapy
Title:Homology-Based Design for Selective GSK-3 Peptide Inhibitors: Patent Applications and Type 2 Diabetes Mellitus
Volume: 8 Issue: 2
Author(s): Camila Chaves Santos, Rodrigo Chaves, Ana Cristina Borges, Michelle Oliveira de Castro and Helio Miranda Costa-Junior
Affiliation:
Keywords: Diabetes mellitus, GSK-3, intracellular signaling, peptide modulator, protein-protein interaction, rational peptide design.
Abstract: Protein kinases function in key steps in several physiopathological events; therefore the development of specific inhibitors to these enzymes presents new opportunities for the treatment of various diseases. Glycogen synthase kinase 3 (GSK-3) is a constitutively active serine/threonine kinase, whose dysfunction has been linked to several cases of insulin-resistant type 2 diabetes mellitus, Alzheimer’s disease and mood disorders. These findings make GSK-3 an attractive target for therapeutics, and several research groups and pharmaceutical companies have made significant efforts to develop new inhibitors with selective activity to different GSK-3 pathways. One of the strategies applied in the development of new inhibitors is based on protein-protein interactions between substrates or docking proteins of specific proteins kinases, creating peptides modulators designed to specifically inhibit those enzymes. Here, we discuss the development, signaling and the patent applications of specific peptides designed to inhibit GSK-3, their patent status and their potential uses in the treatment of GSK-3 specific pathologies.
Export Options
About this article
Cite this article as:
Santos Chaves Camila, Chaves Rodrigo, Borges Cristina Ana, de Castro Oliveira Michelle and Costa-Junior Miranda Helio, Homology-Based Design for Selective GSK-3 Peptide Inhibitors: Patent Applications and Type 2 Diabetes Mellitus, Current Signal Transduction Therapy 2013; 8 (2) . https://dx.doi.org/10.2174/15743624113086660007
DOI https://dx.doi.org/10.2174/15743624113086660007 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Toll-Like Receptor 4 and Heat-Shock Protein 70: Is it a New Target Pathway for Diabetic Vasculopathies?
Current Drug Targets The Role of PTB in Insulin mRNA Stability Control
Current Diabetes Reviews Have We New Therapeutic Strategies in the Treatment of Renovascular Nephropathy?
Current Vascular Pharmacology A Potential Role of Diet in Modulating Peroxisome Proliferator-Activated Receptor (PPAR)-Mediated Signalling in Arthritis
Current Rheumatology Reviews Editorial (Thematic Issue: “An Overview on Proteins of Biomedical Importance in Targeted Therapy of Cancer, Duchenne Muscular Dystrophy and Protein Misfolding Associated Neuropathy: Structure Function Relationship, Mechanism of Action, Role of Small Molecule Antagonist and Future Perspective”)
Current Chemical Biology Can Wogonin be Used in Controlling Diabetic Cardiomyopathy?
Current Pharmaceutical Design Spirolactones: Recent Advances in Natural Products, Bioactive Compounds and Synthetic Strategies
Current Medicinal Chemistry The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease
Current Cardiology Reviews Statins in Diabetes Mellitus
Current Pharmaceutical Design Hypertension and Diabetes: Emphasis on the Renin-Angiotensin System in Atherosclerosis
Current Hypertension Reviews The Coronary Collateral Circulation in Man
Current Cardiology Reviews Adipose Tissue Oxygenation in Obesity: A Matter of Cardiovascular Risk?
Current Pharmaceutical Design Preparation and Evaluation of Multi Particulates Drug Delivery System Using Natural Polymers
Current Drug Delivery Interaction Between Genetic Polymorphisms in Renin-Angiotensin System (RAS) and Therapeutic Efficacy of RAS Blockade in IgA Nephropathy
Current Pharmacogenomics Action of Nanoparticles on Platelet Activation and Plasmatic Coagulation
Current Medicinal Chemistry Genetic Basis of Renal Mass in Rat Models
Current Hypertension Reviews Sol-gel Encapsulation of Biomolecules and Cells for Medicinal Applications
Current Topics in Medicinal Chemistry Fruit Wines Inhibitory Activity Against α-Glucosidase
Current Pharmaceutical Biotechnology Mechanism, Structure, and Inhibition of O-GlcNAc Processing Enzymes
Current Signal Transduction Therapy A Key Role for Connexin Hemichannels in Spreading Ischemic Brain Injury
Current Drug Targets